MDPI and ACS Style
Leypoldt, L.B.; Gavriatopoulou, M.; Besemer, B.; Salwender, H.; Raab, M.S.; Nogai, A.; Khandanpour, C.; Runde, V.; Jauch, A.; Zago, M.;
et al. Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial. Cancers 2023, 15, 4667.
https://doi.org/10.3390/cancers15184667
AMA Style
Leypoldt LB, Gavriatopoulou M, Besemer B, Salwender H, Raab MS, Nogai A, Khandanpour C, Runde V, Jauch A, Zago M,
et al. Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial. Cancers. 2023; 15(18):4667.
https://doi.org/10.3390/cancers15184667
Chicago/Turabian Style
Leypoldt, Lisa B., Maria Gavriatopoulou, Britta Besemer, Hans Salwender, Marc S. Raab, Axel Nogai, Cyrus Khandanpour, Volker Runde, Anna Jauch, Manola Zago,
and et al. 2023. "Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial" Cancers 15, no. 18: 4667.
https://doi.org/10.3390/cancers15184667